- Home
- WGRX vs IMMP Comparison
WGRX vs IMMP Comparison
Compare WGRX & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- IMMP
- Stock Information
- Founded
- WGRX 2022
- IMMP 1987
- Country
- WGRX United States
- IMMP Australia
- Employees
- WGRX N/A
- IMMP N/A
- Industry
- WGRX Other Pharmaceuticals
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- IMMP Health Care
- Exchange
- WGRX Nasdaq
- IMMP Nasdaq
- Market Cap
- WGRX 223.4M
- IMMP 211.1M
- IPO Year
- WGRX 2025
- IMMP N/A
- Fundamental
- Price
- WGRX $2.71
- IMMP $1.85
- Analyst Decision
- WGRX
- IMMP Buy
- Analyst Count
- WGRX 0
- IMMP 2
- Target Price
- WGRX N/A
- IMMP $8.50
- AVG Volume (30 Days)
- WGRX 756.8K
- IMMP 645.2K
- Earning Date
- WGRX 01-01-0001
- IMMP 05-16-2025
- Dividend Yield
- WGRX N/A
- IMMP N/A
- EPS Growth
- WGRX N/A
- IMMP N/A
- EPS
- WGRX N/A
- IMMP N/A
- Revenue
- WGRX $18,128,831.00
- IMMP $3,019,249.00
- Revenue This Year
- WGRX N/A
- IMMP $11.25
- Revenue Next Year
- WGRX N/A
- IMMP $10.22
- P/E Ratio
- WGRX N/A
- IMMP N/A
- Revenue Growth
- WGRX N/A
- IMMP 24.11
- 52 Week Low
- WGRX $2.32
- IMMP $1.32
- 52 Week High
- WGRX $7.04
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- IMMP 53.09
- Support Level
- WGRX N/A
- IMMP $1.44
- Resistance Level
- WGRX N/A
- IMMP $2.71
- Average True Range (ATR)
- WGRX 0.00
- IMMP 0.18
- MACD
- WGRX 0.00
- IMMP 0.03
- Stochastic Oscillator
- WGRX 0.00
- IMMP 28.93
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.